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Received 11 May 2006; received in revised form 25 July 2006; accepted 21 August 2006; Available online 22 September 2006AbstractBackground: Incidence of perioperative in-stent thrombosis associated with myocardial infarction in patients undergoing major lung resection
within 3 months of coronary stenting. Methods: Retrospective multi-institutional trial including all patients undergoing major lung resection
(lobectomy or pneumonectomy) within 3 months of coronary stenting with non-drug-eluting stents between 1999 and 2004. Results: There were
32 patients (29men and 3 women), with age ranging from 46 to 82 years. One, two or four coronary stents were deployed in 72%, 22% and 6% of the
patients, respectively. The time intervals between stenting and lung surgery were <30 days, 30—60 days and 61—90 days in 22%, 53% and 25% of
the patients, respectively. All patients had dual antiplatelet therapy after stenting. Perioperative medication consisted of heparin alone or
heparin plus aspirin in 34% and 66% of the patients, respectively. Perioperative in-stent thrombosis with myocardial infarction occurred in three
patients (9%) with fatal outcome in one (3%). Twenty patients underwent lung resection after 4 weeks of dual antiplatelet therapy as
recommended by the ACC/AHA Guideline Update; however, two out of three perioperative in-stent thrombosis occurred in this group of
patients. Conclusions: Major lung resection performed within 3 months of coronary stenting may be complicated by perioperative in-stent
thrombosis despite 4 weeks of dual antiplatelet therapy after stenting as recommended by the ACC/AHA Guideline Update.
# 2006 Elsevier B.V. All rights reserved.
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Patients with coronary artery disease (CAD) requiring
major lung resection present a vexing dilemma with respect
to appropriate treatment. Anatomical lung resection such as
lobectomy or pneumonectomy may lead to an increased risk
of perioperative myocardial infarction in patients with
severe untreated CAD. Myocardial revascularisation prior
to lung surgery may inappropriately delay the resection with
the risk of disease progression. This holds especially true for
resectable non-small cell lung cancer (NSCLC), which is the
most frequent indication for elective major lung resections.
The ACC/AHA Guideline Update for perioperative cardiovas-
cular evaluation for non-cardiac surgery recommended§ Study of the CLUB THORAX.
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dure of high or intermediate risk in patients with prognostic
high-risk coronary anatomy [1]. Likewise, the Guideline
Update recommended that the indications for percutaneous
coronary interventions (PCI) in the perioperative setting
should be similar to those in the ACC/AHA guidelines for use
of PCI in general. However, surgery should be delayed for at
least 1 week after balloon angioplasty, and if a coronary
stent is used, a delay of ideally 4—6 weeks should occur
before surgery to allow 4 weeks of dual antiplatelet therapy
[1].
We had one perioperative death related to in-stent
thrombosis after uncomplicated lobectomy for NSCLC
following coronary artery stenting, despite 4 weeks of
aspirin and clopidogrel medication after stenting and the
administration of heparin plus aspirin in the perioperative
setting [2]. This retrospective multi-institutional trial was
performed to assess the incidence of perioperative in-stent
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undergoing major lung resection within 3 months of coronary
stenting. Of particular interest was the incidence of
perioperative in-stent thrombosis in patients with 4 weeks
of dual antiplatelet therapy after stenting as recommended
by the ACC/AHA Guideline Update.2. Patients and methods
2.1. Patient enrolment
All patients undergoing lobectomy or pneumonectomy
within 3 months of coronary artery stenting in one of the
above-mentioned institutions between 1999 and 2004 were
identified and the data were retrospectively analysed with
respect to perioperative morbidity and mortality and the
development of in-stent thrombosis associated with myo-
cardial infarction.
2.2. Data collection
Patient demographics and cardiovascular risk factors and
diseases were identified such as persistent smoking at the
time of surgery, diabetes, coexisting carotid or peripheral
artery disease, arterial hypertension as well as cardiac
disorders including CAD, heart failure, arrhythmias, pace-
maker implantation, previous PCI or CABG and the admin-
istration of beta-blockers.
Coronary stenting performed within 3 months of lung
resection was analysed with respect to the nature and
number of stents deployed, the indication for stenting
(symptomatic coronary artery disease vs asymptomatic
severe CAD detected during exercise testing), the time
interval between stenting and lung surgery (<30 days vs 30—
60 days vs 61—90 days) and antiplatelet therapy.
The extent of resection (lobectomy or pneumonectomy)
and the nature of underlying lung disease were noted as well
as the perioperative anticoagulation regimen (heparin vs
heparin plus antiplatelet agents).
Perioperative complications and mortality after lung
resection were analysed up to 30 days after surgery with
special consideration of local and distant haemorrhage and
in-stent thrombosis associated with myocardial infarction.
All patients were admitted to the intensive care unit after
lung resection and perioperative cardiac events were
recorded on the base of clinical symptoms and postoperative
ECG changes. Patients with clinical, electrocardiographic or
enzymologic suspicion of in-stent thrombosis associated with
myocardial infarction underwent coronary angiography. A
diagnosis of in-stent thrombosis required confirmation by
coronary angiography.3. Results
3.1. Patient demographics
Thirty-two patients were identified as having a lobectomy
or a pneumonectomy within 3 months of coronary artery
stenting between 1999 and 2004. There were 29 men and 3women with a mean age of 64.3 years, ranging from 46 to 82
years.
3.2. Cardiovascular risk factors and diseases
Persistent smoking was found in 11 patients (34%),
diabetes mellitus in 5 (16%), peripheral vascular disease in
10 (31%) and arterial hypertension in 18 (56%). Symptomatic
CAD with angor or myocardial infarction was found in 17
patients (53%), requiring previous PCI in 9 (28%) or CABG in 2
(6%). A history of heart failure was found in 2 patients (6%)
and atrial fibrillation in 2 (6%). Eleven patients (34%) had
beta-blocker administration.
3.3. Coronary stenting prior to lung resection
Fifteen patients (47%) underwent coronary stenting for
asymptomatic CAD detected during exercise testing. Non-
drug-eluting stents were applied in all patients. One stent
was implanted in 23 patients (72%), two stents in 7 patients
(22%) and four stents in 2 patients (6%). The time interval
between stenting and lung resection was less than 30 days in
7 patients (22%), 30—60 days in 17 patients (53%) and 61—90
days in 8 patients (25%). All patients received dual
antiplatelet therapy with aspirin and clopidogrel after
stenting. Clopidogrel was stopped in all the patients 7—10
days before surgery. Aspirin was stopped before surgery in 11
patients (34%) and continued during the perioperative period
in 21 (66%). Twenty patients underwent lung resection after 4
weeks of dual antiplatelet therapy as recommended by the
ACC /AHA Guideline Update.
3.4. Lung resection
The indication for resection was non-small cell lung
cancer in 30 patients (94%) and haemoptysis due to infection
in 2 (6%). Lobectomy was performed in 27 patients (84%), left
pneumonectomy in 4 (13%) and right pneumonectomy in 1
(3%). Perioperative anticoagulation beginning 1 day before
the operation consisted in the administration of heparin in 11
patients (34%) and of heparin plus aspirin in 21 patients (66%).
Thirty patients (94%) received low molecular weight heparin
(FraxiparineW 0.4 s.c. 1  daily) and two (6%) had continuous
intravenous heparin administration (20,000 IU/day).
3.5. Perioperative mortality and morbidity after lung
resection
Three patients (9%) died within 30 days after resection.
Two of them (6%) succumbed from adult respiratory distress
syndrome occurring after bilobectomy in one and after
lobectomy following radiochemotherapy in one. One patient
(3%) died from myocardial infarction due to in-stent
thrombosis.
Non-fatal, non-cardiac complications were observed in 6
patients (19%), including empyema in 2, hemothorax in 2,
retroperitoneal hematoma in 1 and chylothorax in 1. Non-
fatal cardiac complications were found in 6 patients (19%),
including arrhythmias in 4 (13%) and coronary in-stent
thrombosis in 2 (6%). Overall, 3 patients (10%) revealed
postoperative bleeding complications (hemothorax in 2 and
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reoperations but blood transfusions in 2 patients.
Overall, 3 of the 32 patients (9%) developed perioperative
in-stent thrombosis documented by coronarography and
associated with myocardial infarction. Two of these patients
underwent single stent deployment for asymptomatic CAD
followed by pneumonectomy and lobectomy after an interval
between stenting and lung resection of 31 and 90 days,
respectively. In-stent thrombosis and myocardial infarction
were followed by an uneventful course without cardiac
reinterventions in both patients. One patient underwent
uneventful lobectomy 44 days after deployment of four
stents for symptomatic CAD. He developed in-stent throm-
bosis and myocardial infarction in the recovery room and
underwent PCI without fibrinolysis. He then developed
reinfarction after initial successful recanalisation, and died
4 days after lobectomy.
Twenty patients underwent lung resection according to
the recommendations of the ACC/AHA Guideline Update with
4 weeks of dual antiplatelet therapy after stenting; however,
two out of three perioperative in-stent thrombosis occurred
in this group of patients.4. Comment
Several reports suggest that coronary bypass grafting prior
to non-cardiac surgery may reduce the risk of perioperative
myocardial infarction after non-cardiac surgery. This holds
especially true for patients with a critical left main stem
stenosis or severe proximal three vessel disease in the
presence of positive exercise testing or impaired left
ventricular function [3—5]. The influence of prior coronary
artery bypass surgery (CABG) versus medical therapy for
reducing the risk of postoperative cardiac complications
after non-cardiac surgery was assessed by use of the Coronary
Artery Surgery Database [4]. Among 1961 patients undergoing
higher risk (abdominal, vascular, thoracic) surgery, prior
CABG was associated with fewer postoperative deaths (1.7%
vs 3.3%, p = 0.03) and myocardial infarction (0.8% vs 2.7%,
p = 0.002) compared with medically managed coronary
disease [4]. Likewise, abdominal aortic aneurysm repair
performed within 60 days after CABG was associated with a
low perioperative mortality (0%) and myocardial infarction
rate (6%) in patients with severe coronary artery disease [5].
However, the role of PCI prior to non-cardiac surgery
remains unclear in this respect. Percutaneous coronary
balloon angioplasty performed before non-cardiac surgery
seems to reduce the risk of perioperative cardiac complica-
tions in patients with severe CAD [6—9]. In the era of coronary
stenting, these patients faired worse as a consequence of
perioperative in-stent thrombosis especially if non-cardiac
surgery was performed within 4 weeks of stenting [10,11].
Coronary stenting adds thrombogenic material to a
prothrombotic perioperative milieu, which holds especially
true in the context of oncological procedures [12]. A recent
experimental study endorses the impression that surgical
interventions may be accompanied by a prothrombotic state
demonstrating that wound monocytes preferentially accel-
erate activation of factor VII and factor X in the presence of
wound plasma tissue factor during surgery [13]. Thisrepresents a novel mechanism for thrombin generation
during surgical interventions and may explain the periopera-
tive thrombotic and non-surgical bleeding complications,
which may be observed in this respect. In addition, increased
concentrations of circulating plasma tissue factor also occur
in a variety of diseases such as cardiovascular disorders and
malignancies that may further increase the risk of throm-
boembolic events in the perioperative setting [13].
Several authors have questioned an uncritical approach in
the context of coronary stenting before non-cardiac surgery
[1,10,12,14]. However, most of these studies investigated
patients with vascular procedures. There is actually no data
available regarding the risk of in-stent thrombosis after
major lung resection performed after coronary stenting. Our
results indicate a 9% incidence of perioperative in-stent
thrombosis associated with myocardial infarction after major
lung resection performed within 3 months of coronary
stenting. Moreover, two of three of perioperative in-stent
thrombosis occurred in the group of patients receiving 4
weeks of dual antiplatelet therapy after stenting as
suggested by the recommendations of the ACC /AHA
Guideline Update.
Caution in the interpretation of the results is indicated
because of the small sample size and the retrospective data
collection. However, an incidence of 9% in-stent thrombosis
after coronary stenting is substantially higher than that
reported in routine clinical practice. In-stent thrombosis
after elective coronary stenting occurs in less than 1% of
cases [15]. A recent publication reported a 0.5% incidence of
in-stent thrombosis after successful coronary stenting with
non-drug-eluting stents and dual antiplatelet therapy [16].
As the number of patients scheduled for lung surgery after
coronary stenting will increase in near future, strategies for
prevention of perioperative in-stent thrombosis are
required. There is some evidence that vascular repair after
stenting may take a protracted period of time. Moreover, this
remodelling process may be further lengthened after
deployment of drug-eluting stents that inhibit the repair
process in order to prevent neointimal hyperplasia and
restenosis. A period of 4 weeks of dual antiplatelet
medication after stenting may not be sufficient to allow
reepithelialisation of the stented vessel. Since there is
evidence that dual antiplatelet therapies have additional
benefits for up to 12 months following coronary stenting [17]
it might be appropriate to maintain aspirin and clopidogrel
administration during the perioperative phase of lung surgery
following coronary stenting irrespective of the time interval
between stenting and lung resection. Aspirin and clopidogrel
administration during surgery may increase the risk of
bleeding and may interfere with epidural analgesia. How-
ever, these drawbacks have to be balanced with the risk of
perioperative in-stent thrombosis and its inherent high
mortality in case of withdrawal of aspirin and clopidogrel
before surgery, especially in the presence of drug-eluting
stents. Patients with coronary artery disease requiring
revascularisation prior to high-risk non-cardiac surgery
should preferably be treated by percutaneous coronary
balloon angioplasty instead of stenting. However, if non-
cardiac surgery is required after coronary stenting, dual
antiplatelet therapy (aspirin and clopidogrel) should be used
in the perioperative setting.
P.-Y Brichon et al. / European Journal of Cardio-thoracic Surgery 30 (2006) 793—796796In conclusion, our results extend previous investigations
indicating a persistent risk of perioperative in-stent throm-
bosis after coronary stenting in the setting of lung resection
performed within 3 months of stenting. Larger prospective
trials are required to determine the risk of perioperative in-
stent thrombosis in patients with coronary stents undergoing
major lung resections.
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